Stock Analysis

Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?

HLSE:REG1V
Source: Shutterstock

While Revenio Group Oyj (HEL:REG1V) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the HLSE, rising to highs of €54.30 and falling to the lows of €40.82. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Revenio Group Oyj's current trading price of €43.92 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Revenio Group Oyj’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Revenio Group Oyj

What Is Revenio Group Oyj Worth?

The stock seems fairly valued at the moment according to my valuation model. It’s trading around 2.7% below my intrinsic value, which means if you buy Revenio Group Oyj today, you’d be paying a fair price for it. And if you believe that the stock is really worth €45.14, then there’s not much of an upside to gain from mispricing. Although, there may be an opportunity to buy in the future. This is because Revenio Group Oyj’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

Can we expect growth from Revenio Group Oyj?

earnings-and-revenue-growth
HLSE:REG1V Earnings and Revenue Growth September 17th 2022

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Revenio Group Oyj's earnings over the next few years are expected to increase by 87%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What This Means For You

Are you a shareholder? It seems like the market has already priced in REG1V’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping tabs on REG1V, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

It can be quite valuable to consider what analysts expect for Revenio Group Oyj from their most recent forecasts. Luckily, you can check out what analysts are forecasting by clicking here.

If you are no longer interested in Revenio Group Oyj, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About HLSE:REG1V

Revenio Group Oyj

Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.

Flawless balance sheet with reasonable growth potential.